10.13
0.11 (1.10%)
| Penutupan Terdahulu | 10.02 |
| Buka | 9.71 |
| Jumlah Dagangan | 255,286 |
| Purata Dagangan (3B) | 595,431 |
| Modal Pasaran | 492,198,464 |
| Harga / Jualan (P/S) | 8.11 |
| Harga / Buku (P/B) | 5.53 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -6.04 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -100.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8.29% |
| Nisbah Semasa (MRQ) | 13.93 |
| Aliran Tunai Operasi (OCF TTM) | -59.79 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -36.41 M |
| Pulangan Atas Aset (ROA TTM) | -33.29% |
| Pulangan Atas Ekuiti (ROE TTM) | -68.14% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Artiva Biotherapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | 3.5 |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.38 |
|
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 19.99% |
| % Dimiliki oleh Institusi | 89.73% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Revelation Capital Management, Llc | 31 Mar 2026 | 299,311 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9.24 | - | 166,906 | 1,513,785 |
| Jumlah Keseluruhan Kuantiti Bersih | 166,906 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 1,513,785 | |||
| Purata Pembelian Keseluruhan ($) | 9.24 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Pengarah | 17 Jul 2026 | Beli (+) | 7,882 | 9.76 | 76,928 |
| RA CAPITAL MANAGEMENT, L.P. | Pengarah | 16 Jul 2026 | Beli (+) | 152,472 | 9.04 | 1,378,347 |
| RA CAPITAL MANAGEMENT, L.P. | Pengarah | 13 Jul 2026 | Beli (+) | 6,552 | 8.93 | 58,509 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |